Captrust Financial Advisors An2 Therapeutics, Inc. Transaction History
Captrust Financial Advisors
- $38.8 Billion
- Q1 2025
A detailed history of Captrust Financial Advisors transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 10,000 shares of ANTX stock, worth $10,600. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000
Previous 28,667
65.12%
Holding current value
$10,600
Previous $38,000
65.79%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ANTX
# of Institutions
38Shares Held
13.6MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN5.75MShares$6.09 Million6.33% of portfolio
-
Almitas Capital LLC Santa Monica, CA1.31MShares$1.39 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.1 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1MShares$1.06 Million0.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY583KShares$617,7360.62% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $20.6M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...